One-Hour test could revolutionize pneumonia treatment in hospitals
NCT ID NCT07585604
First seen Jun 27, 2026 · Last updated Sep 18, 2026 · Updated 2 times
Summary
This study compares a rapid test that identifies pneumonia-causing bacteria in about one hour to standard lab methods that take 2-4 days. Researchers want to see if the faster test helps doctors choose the right antibiotics sooner for 150 hospitalized patients with pneumonia. The goal is to improve treatment and reduce antibiotic resistance.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 150 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2026
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥18 years. * Clinical diagnosis of hospital-acquired pneumonia or clinically relevant tracheobronchitis requiring antimicrobial treatment, with or without mechanical ventilation. * No respiratory cultures collected in the last 72 hours (except for the culture that will potentially be evaluated in the study-trigger for inclusion). * Agreement from the patient or legal representative to sign the Informed Consent Form (ICF). Exclusion Criteria: * Inadequate respiratory samples according to laboratory cutoffs for squamous epithelial cells and polymorphonuclear leukocytes (sputum or endotracheal aspirate). * Incarcerated populations. * Pregnant women.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Clinically relevant tracheobronchitis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Hospital de Clínicas de Porto Alegre
RECRUITINGPorto Alegre, Rio Grande do Sul, 90035-003, Brazil
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common steroid tame deadly lung infections in the ICU?
- AI could outsmart bacteria: a smarter way to choose antibiotics?
- Artificial intelligence may forecast pneumonia after heart surgery
- Does the setting of care affect whether kids finish their antibiotics?
- Inhaled antibiotics aim to beat pneumonia in ECMO patients
- New study aims to uncover why some pneumonia patients need ventilators